• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prognostic markers could extend adjuvant immunotherapy to high-risk stage IB/IIA melanoma: A modeling study.

作者信息

Tan Samuel X, Muller Nicholas Michael, Zhou Chenhao, Walpole Euan, Smithers B Mark, Whiteman David C, Khosrotehrani Kiarash

机构信息

Frazer Institute, Dermatology Research Centre, Experimental Dermatology Group, The University of Queensland, Brisbane, Australia.

Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia.

出版信息

JAAD Int. 2024 Oct 30;18:86-87. doi: 10.1016/j.jdin.2024.09.010. eCollection 2025 Feb.

DOI:10.1016/j.jdin.2024.09.010
PMID:39639982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11617983/
Abstract
摘要

相似文献

1
Prognostic markers could extend adjuvant immunotherapy to high-risk stage IB/IIA melanoma: A modeling study.预后标志物可将辅助免疫治疗扩展至高危ⅠB/ⅡA期黑色素瘤：一项建模研究。
JAAD Int. 2024 Oct 30;18:86-87. doi: 10.1016/j.jdin.2024.09.010. eCollection 2025 Feb.
2
Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer.18F-FDG PET/CT 中 TLR 对切缘阴性ⅠB 期和ⅡA 期非小细胞肺癌患者预后的预测价值。
Eur Radiol. 2023 Oct;33(10):7274-7283. doi: 10.1007/s00330-023-09641-w. Epub 2023 Apr 15.
3
Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts.预测基因表达谱检测以指导辅助治疗的应用：一项黑色素瘤专家调查。
Cancer Med. 2023 Dec;12(24):22103-22108. doi: 10.1002/cam4.6819. Epub 2023 Dec 14.
4
[Prognostic factors of stage IB and IIA carcinoma of the cervix treated by surgery].[手术治疗的ⅠB期和ⅡA期宫颈癌的预后因素]
Zhonghua Zhong Liu Za Zhi. 2004 Aug;26(8):490-2.
5
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.利用临床病理和基因表达模型识别 I/IIA 期黑色素瘤患者中疾病复发的高危人群。
Eur J Cancer. 2020 Nov;140:11-18. doi: 10.1016/j.ejca.2020.08.029. Epub 2020 Oct 5.
6
Efficacy and safety of consolidation chemotherapy after adjuvant therapy in stage IB-IIA cervical cancer patients with risk factors: a retrospective single-center study.辅助治疗后巩固化疗在伴有危险因素的IB-IIA期宫颈癌患者中的疗效与安全性：一项回顾性单中心研究
Front Oncol. 2024 Mar 21;14:1374195. doi: 10.3389/fonc.2024.1374195. eCollection 2024.
7
[Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].[伴有危险因素的Ib-IIa期宫颈癌不同术后辅助治疗的结果]
Zhonghua Fu Chan Ke Za Zhi. 2013 Dec;48(12):920-4.
8
A Nomogram to Predict the Overall Survival of Patients With Resected T1-2N0-1M0 Non-Small Cell Lung Cancer and to Identify the Optimal Candidates for Adjuvant Chemotherapy in Stage IB or IIA Non-Small Cell Lung Cancer Patients.列线图预测 T1-2N0-1M0 期可切除非小细胞肺癌患者的总生存，并确定 IB 期或 IIA 期非小细胞肺癌患者辅助化疗的最佳候选者。
Cancer Control. 2023 Jan-Dec;30:10732748231197973. doi: 10.1177/10732748231197973.
9
Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma.用于美国癌症联合委员会第8版I-IIA期皮肤黑色素瘤辅助治疗试验招募的具有七种生物标志物预后特征的高危患者的识别。
Eur J Cancer. 2023 Mar;182:77-86. doi: 10.1016/j.ejca.2023.01.002. Epub 2023 Jan 7.
10
Outcomes and prognostic factors of patients with stage IB and IIA pancreatic cancer according to the 8 edition American Joint Committee on Cancer criteria.根据美国癌症联合委员会第8版标准，IB期和IIA期胰腺癌患者的预后及预后因素
World J Gastroenterol. 2017 Apr 21;23(15):2757-2762. doi: 10.3748/wjg.v23.i15.2757.

本文引用的文献

1
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.辅助纳武利尤单抗治疗 IIB/C 期黑色素瘤：CheckMate 76K 随机、III 期研究的主要结果。
Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16.
2
31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration.31-基因表达谱检测在皮肤黑色素瘤中的应用及其在基于人群的分析中的生存结果：SEER 合作研究。
JCO Precis Oncol. 2023 Jun;7:e2300044. doi: 10.1200/PO.23.00044.
3
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.帕博利珠单抗对比安慰剂作为 IIB 期或 IIC 期黑色素瘤（KEYNOTE-716）的辅助治疗：一项多中心、双盲、随机、III 期试验的无远处转移生存结果。
Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18.
4
Comparative performance of predictors of death from thin (≤ 1·0 mm) melanoma.薄型（≤1.0 mm）黑色素瘤死亡预测指标的比较性能。
Br J Dermatol. 2021 Oct;185(4):849-851. doi: 10.1111/bjd.20480. Epub 2021 Jul 22.
5
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.黑色素瘤分期：美国癌症联合委员会第八版癌症分期手册中基于证据的变化。
CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.